Inside Precision Medicine Published Online: August 18, 2022 Read the Full Article >> Artificial intelligence (AI) has promised major breakthroughs in clinical development success. While the hype has sometimes seemed overblown, AI is starting to deliver on those promises through real-world impact. AI is not a silver bullet for all challenges, but in specific applications,[…]
Read the Press Release >> BOSTON, June 23, 2022 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by[…]
First Published June 22, 2022 – Multiple Sclerosis Journal Assessment of multiple sclerosis (MS) disease activity is critical for understanding treatment effectiveness, informing treatment decisions, and monitoring disease progression. Magnetic resonance imaging (MRI) findings, clinician-administered assessments, and patient questionnaires are used to measure disease activity and track changes over time. The Expanded Disability Status Scale[…]
July 19, 2022 11:00 AM EDT Register>> Real-world data (RWD) can provide valuable insights into treatment effectiveness and be used to generate evidence for decision making. Understanding which data, when and how to use it, and special considerations when leveraging for regulatory and other stakeholders are all critical to success for RWD comparative effectiveness research[…]
BioPharma Dive Online Read the Full Article>> Health inequities around the world produce disparities of a shocking magnitude. For example, life expectancy from birth ranges from approximately 55 to 85 years old depending on the country in which a child is born. Linked with degrees of social disadvantage, these same profound differences can be seen[…]
